CLSN Phase 3 interim analysis due this year. ARQL Phase 2 HCC data due early 2012.

Nov 10, 2011 No Comments by

ArQule, Inc. (NASDAQ: ARQL) noted that in the last quarter patient recruitment in the Phase 2 trial with tivantinib, an oral, selective inhibitor of the c-MET receptor tyrosine kinase, in hepatocellular carcinoma (HCC), had been completed and expects to have data available very early in 2012.

Celsion Corporation (NASDAQ: CLSN) maintained today that it interim analysis of its HEAT Phase 3 trial in patients with non-resectable primary liver cancer (hepatocellular carcinoma or HCC), is expected by the end of 2011, with a final data readout in late 2012.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it expects to initiate a Phase 1-2 clinical trial of of ganetespib with radiation and chemotherapy by Q1 2012.

 

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “CLSN Phase 3 interim analysis due this year. ARQL Phase 2 HCC data due early 2012.”

Leave a Reply